Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-154 in glucocorticoid-dependent polymyalgia rheumatica
NL-OMON54200Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing ABBV-154 + glucocorticoid taper with Placebo + glucocorticoid taper (2 arms). Primary endpoint: Time to flare by Week 24. Started Oct 2021; status: completed.
02
Drugs
ABBV-154
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON54200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54200.